Pharming Group NV(PHGN)

Description: Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

---

Keywords: Biopharmaceutical Medication Rare Diseases Gene Therapy Orphan Drug Hereditary Angioedema Angioedema Complement Deficiency Treatment Of Rare Diseases Pharming C1 Inhibitor Acute Hereditary Angioedema Ruconest Delta Syndrome Leniolisib

---

Home Page: www.pharming.com

Darwinweg 24
Leiden, 2333 CR
Netherlands
Phone: 31 71 524 7400

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)